Randomized, Double-blind, Comparative to Placebo Study to Evaluate the Safety and Efficacy of Nebulized PC945 When Added to Systemic Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: PULMOCIDE LTD
- Phase: III
- Execution start: 04/10/2022
- End of execution: 02/06/2024
- PI: PEDRO ANTONIO GONZALEZ SIERRA